Dergiler / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 12

Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs

Sayfa
963–969
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The mRNA and protein expression levels of Cav1.2 and Nav1.5? were apparently down-regulated in the paced group (p<0.01), but after cilostazol treatment, both of these subunits were up-regulated significantly (p<0.01).Conclusion: Cilostazol may have protective effects on RAP-induced atrial ionic remodeling

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Ionic remodeling has a close correlation with the occurrence of atrial fibrillation (AF).
📊
Temel Bulgular & Veri:The purpose of this study was to assess the efficacy of cilostazol, an oral phosphodiesterase 3 inhibitor, for preventing atrial ionic remodeling in long-term rapid atrial pacing (RAP) dogs.Methods: We use the methods of patch-clamp and molecular biology to investigate the effect of cilostazol on ion channel and channel gene expression in long-term RAP dogs.
💡
Sonuç & Katkı:The mRNA and protein expression levels of Cav1.2 and Nav1.5? were apparently down-regulated in the paced group (p<0.01), but after cilostazol treatment, both of these subunits were up-regulated significantly (p<0.01).Conclusion: Cilostazol may have protective effects on RAP-induced atrial ionic remodeling
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Ionic remodeling has a close correlation with the occurrence of atrial fibrillation (AF). Atrial tachypacing remodeling is associated with characteristic ionic remodeling. The purpose of this study was to assess the efficacy of cilostazol, an oral phosphodiesterase 3 inhibitor, for preventing atrial ionic remodeling in long-term rapid atrial pacing (RAP) dogs.Methods: We use the methods of patch-clamp and molecular biology to investigate the effect of cilostazol on ion channel and channel gene expression in long-term RAP dogs. Twenty-one dogs were randomly assigned to sham, control paced, and paced+cilostazol (5 mg/kg/d, cilo) groups, with 7 dogs in each group. The sham group was instrumented with a pacemaker but without pacing. RAP at 500 beats/min was maintained for 2 weeks in the paced and cilo groups. During the pacing, cilostazol was given orally in the cilo group. Whole-cell patch-clamp technique was used to record atrial L-type Ca2+ (ICaL) and fast sodium channel (INa) ionic currents. Western blot and RT-PCR were applied to estimate the gene expression of the ICaL?) 1C (Cav1.2) and INav1.5?) Nav1.5?) subunits. Statistical analysis was performed using SPSS 13.0.Results: The density of ICaL and INa currents (pA/pF) was significantly reduced in the paced group (ICaL: -6.55±1.42 vs. -4.46±0.59 pA/pF; INa: -48.24±10.54 vs. -30.48±5.20 pA/pF, p<0.01). The paced+cilo group could not increase the density of ICaL currents (ICaL: -4.37±1.25 pA/pF, p>0.05), while the INa currents were recovered (-44.54±12.65 pA/pF, p<0.01) compared with the paced group. The mRNA and protein expression levels of Cav1.2 and Nav1.5? were apparently down-regulated in the paced group (p<0.01), but after cilostazol treatment, both of these subunits were up-regulated significantly (p<0.01).Conclusion: Cilostazol may have protective effects on RAP-induced atrial ionic remodeling

🔖

Bu Makaleye Atıf Yap

ZHAO, Z., Lİ, W., WANG, X., CHEN, Y., LI, J., YANG, W., CHENG, L., LİU, E., LIU, T., LI, G. (2015). Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 12, 963–969. https://ajindex.com/articles/365636

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010
  2. [CrossRef] Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010
  3. [CrossRef] Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mecha- nisms. Can J Cardiol 2011
  4. [CrossRef] Moro C, Hernández-Madrid A, Matía R. Non-antiarrhythmic drugs to pre- vent atrial fibrillation. Am J Cardiovasc Drugs 2010
  5. [CrossRef] Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream thera- pies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011
  6. [CrossRef] Liu E, Xu Z, Li J, Yang S, Yang W, Li G. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remod- eling. Int J Cardiol 2011
  7. [CrossRef] Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995
  8. [CrossRef] Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001
  9. [CrossRef] Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown) 2011
  10. [CrossRef] Han SW, Lee SS, Kim SH, Lee JH, Kim GS, Kim OJ, et al. Effect of Cilostazol in acute Lacunar Infarction based on Pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double- blind, placebo-controlled trial. Eur Neurol 2013
  11. [CrossRef] Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003
  12. [CrossRef] Kim MJ, Park KG, Lee KM, Kim HS, Kim SY, Kim CS, et al. Cilostazol inhibits vascular smooth muscle cell growth by down regulation of the transcription factor E2F. Hypertension 2005
  13. [CrossRef] Watanabe K, Ikeda S, Komatsu J, Inaba S, Suzuki J, Sueda S, et al. Effect of cilostazol on vasomot